Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Stock Singapore S.E.
Equities
T14
CNE100000924
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.98 USD | -0.50% | +0.51% | -4.35% |
Apr. 30 | Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3% | MT |
Apr. 30 | Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Recommends Dividend | CI |
Sales 2024 * | 9.05B 1.25B | Sales 2025 * | 9.96B 1.38B | Capitalization | 22.82B 3.15B |
---|---|---|---|---|---|
Net income 2024 * | 1.17B 162M | Net income 2025 * | 1.4B 193M | EV / Sales 2024 * | 2.52 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.29 x |
P/E ratio 2024 * |
23
x | P/E ratio 2025 * |
19.3
x | Employees | 4,619 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 31.14% |
1 day | -0.50% | ||
1 week | +0.51% | ||
Current month | -1.00% | ||
1 month | -1.49% | ||
3 months | +17.16% | ||
6 months | +15.79% | ||
Current year | -4.35% |
Managers | Title | Age | Since |
---|---|---|---|
Lei Wang
CEO | Chief Executive Officer | 53 | 22-08-21 |
Hong Zhou
CTO | Chief Tech/Sci/R&D Officer | 54 | 12-11-30 |
42 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ping Zhang
BRD | Director/Board Member | 55 | 19-09-29 |
Yoke Pheng Liew
BRD | Director/Board Member | 68 | 20-06-04 |
Hong Zhou
CTO | Chief Tech/Sci/R&D Officer | 54 | 12-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 1.98 | -0.50% | 41 300 |
24-05-02 | 1.99 | -0.50% | 68,700 |
24-04-30 | 2 | -0.50% | 240,900 |
24-04-29 | 2.01 | +0.50% | 389,300 |
24-04-26 | 2 | +1.52% | 400,900 |
Delayed Quote Singapore S.E., May 03, 2024 at 04:59 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+39.33% | 6.11B | |
-18.38% | 4.35B | |
-9.17% | 3.18B | |
-3.41% | 2.51B | |
+48.74% | 1.98B | |
-4.82% | 1.74B | |
-1.24% | 1.63B | |
-8.96% | 1.6B | |
+39.87% | 1.44B |
- Stock Market
- Equities
- 600329 Stock
- T14 Stock